fashion -WSS

fashion

author：knowledge 2025-08-26 23:44:06 - browse：2

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： STAT Summit: The economic case for universal basic health care

entertainment

WSS

Brazil's Jair Bolsonaro is barred from running for office until 2030

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

fashion

explore

At least 13 dead in Texas as scorching temps continue

Health tech investors get more selective as pandemic boom fades

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roche acquires Telavant from Roivant, adding experimental IBD treatment

How one medical school became remarkably diverse

Brazil's Jair Bolsonaro is barred from running for office until 2030

Cancer drug shortages should be causing more outrage

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

As demand for Covid shots wanes, Moderna seeks its next success

ADCs take center stage as promising cancer treatments

focus

Why a market frenzy over new weight loss drugs defies logic

Roche drug slashes death risk in early

Results on Novartis prostate cancer therapy could expand its use

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

GOP inquiry over gain

Results on Novartis prostate cancer therapy could expand its use

hotspot

entertainment

hotspot

explore